Trial Condition(s):
Hypertension
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
Bayer Identifier:
13599
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months
Inclusion Criteria
- Hypertensive patients seen by the physician requiring antihypertensive treatment
Exclusion Criteria
- According to the local drug information
Trial Summary
Enrollment Goal
2052
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Kinzal/Pritor (Telmisartan, BAY68-9291)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Switzerland | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Data collection on hypertension and its treatment with Kinzal®/ Kinzalplus®
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
2
Primary Outcome
- Blood pressureTimeframe: After 1-2 weeks, 1month, 3-4 months
Secondary Outcome
- Change in Mean heart rate (bpm)Timeframe: Baseline and 3-4 month
- Change in Mean Weight (kg)Timeframe: Baseline and 3-4 month
- Change in Mean laboratory parameters (total cholesterol, LDL, HDL, triglyceride, fasting blood glucose)Timeframe: Baseline and 3-4 month
- Patient Medical History: Duration of hypertension, Pre-treatment of hypertension, Comorbidities and Concomitant treatmentTimeframe: Baseline
- Final evaluation of efficacy (very good, good, sufficient, insufficient) and tolerability (very good, good, sufficient, insufficient) of treatment by the physician.Timeframe: After 3-4 month
Additional Information
Copyright © Bayer
Powered by
